Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lipotropin (LPH) has been evaluated as a potential tumor marker using a sensitive beta melanocyte-stimulating hormone (beta MSH) radioimmunoassay. All 79 acetic acid extracts of carcinomas of lung, colon, stomach, esophagus and breast contained LPH in concentrations greater than blood; 61 of 79 extracts contained LPH in larger amounts than control tissues from patients without cancer. In a blind prospective study, plasma LPH was quantified in 107 patients admitted for work-up because of an abnormality on a chest roentgenogram. Thirty-one of 33 patients subsequently diagnosed as having benign lesions had plasma LPH within the 95 per cent confidence limits of normal subjects whereas 28 (36 per cent) of the 74 patients subsequently diagnosed histologically as having primary lung carcinoma had elevated levels. In control studies, 13 of 100 patients with chronic obstructive pulmonary disease had elevated plasma LPH levels; three of the 13 with elevated levels and four with normal levels have been diagnosed, during the two years of follow-up, as having lung carcinoma. In control studies of 23 patients with granulomatous lung disease, 22 had normal levels of LPH. In those with carcinoma of the colon elevated plasma LPH levels were observed in two of 21 untreated patients and in 11 of 61 patients receiving noncurative chemotherapy. Elevated plasma LPH levels were also observed in 10 of 59 patients with breast cancer, eight of 28 with pancreatic cancer, eight of 22 with gastric or esophageal cancer, six of 16 with renal cancer, four of eight with prostatic cancer, one of seven with cervical cancer and one of six with ovarian cancer. We conclude, an elevated LPH level is frequently observed in blood and tumor tissue from patients with various types of carcinoma.
 ...
PMID:Ectopic production of lipotropin by cancer. 43 67

The Japanese-American population was particularly well suited for the study of cancer occurrence because: 1) An American-born population as well as the immigrant Japanese-American population could be studied; 2) good cancer incidence and mortality data from Japan could be compared with data from the United States; and 3) some differences in the rate of occurrence of several specific cancer sites in Japan as compared with the United States were striking. The most significant of these involved the gastrointestinal tract and sex organs. Data were presented concerning cancer incidence rates for the Japanese-American population of the San Francisco Bay area. The high gastric rates for the Japanese in Japan were reduced in a stepwise fashion in the immigrant Japanese-American population to the American-born Japanese who were approaching the low rate of the United States. Colon cancer rates, which were low in Japan, approached the rates in the United States in both the immigrants from Japan and in Japanese Americans. The low rates of cancers of the breast, uterine corpus, and ovary of Japanese women in Japan and for prostate cancer among men rapidly approached the higher rates for these cancer sites that existed in the United States. A study of nutritional factors related to the increase of cancer of the breast in Japanese Americans is being conducted.
 ...
PMID:Breast cancer among American Japanese in the San Francisco Bay area. 61 35

The recording of new cases of cancer in the Bas-Rhin department interest about 883 000 persons in 1975. 3 073 cancer cases have been registered. The data show an incidence of 424 per 100 000 for male population and 309 per 100 000 among female population. Among male population: lung cancer is the most frequent, it represents 17.1 per cent of male cancers with an incidence of 72.5. In second position cancer of the rectum and recto-sigmoid which represents 7.9 per cent of cancers; it has an incidence of 33.4 per cent. Then followed in this order: prostate cancer with an incidence of 32.3, colon cancer with an incidence of 30.1, cancer of the stomach, and bladder. Among female population: breast cancer is by far the most frequent, it represents 27.5 per cent of all cancers, the incidence is 88.4; next corpus uteri cancer with an incidence of 29.5; colon cancer with an incidence of 25.4, followed by cervix uteri cancer with an incidence of 22.1. The genital localizations, on the whole represent 23.2 per cent of cancers with an incidence of 75.3. It is too early to interprete the recorded disparities among the different districts, nevertheless, one can think that the low rates reported in some districts is due to an under-recording.
 ...
PMID:[Incidence of new cases of cancer in 1975 in the Department of Bas-Rhin]. 66 79

Mortality rates from multiple sclerosis show a well-known north-south gradient, both within the United States and internationally. Mortality rates from prostate cancer show a similar gradient and are significantly correlated with multiple sclerosis (MS) mortality and MS prevalence. This finding adds prostate cancer to the set of diseases whose geographic distributions are significantly correlated with MS and whose members include colon cancer, dental caries, and Parkinson's disease. Review of the literature indicates that these clinically dissimilar diseases may share an aberration in vitamin (hormone) D. Recent evidence demonstrating a multi-faceted role for vitamin D in immunoregulation suggests that a vitamin D aberration may also contribute to the etiology of MS. A vitamin D hypothesis can illuminate several unexplained features of the epidemiology of MS and suggests opportunities for epidemiologic, laboratory, and clinical investigation.
 ...
PMID:Multiple sclerosis and prostate cancer: what do their similar geographies suggest? 129 88

Diet can play a key role in the pathogenesis of cancer. Diets high in fat and low in fiber predispose individuals to colon cancer. A high-fat diet is also implicated in breast cancer and prostate cancer. The dietary fat-cancer linkage is supported by epidemiological evidence, animal studies, and prospective trials. The antioxidants vitamin E, ascorbic acid, and beta-carotene have a protective effect and act as antipromoters of carcinogenesis. A diet of less than or equal to 10% of calories from fat and less than or equal to 40 g of fiber daily that includes fruits and vegetables will prevent up to 35% of cancers.
 ...
PMID:Nutrition and cancer. 132 5

In the United States, little has been done to compare the cancer risk of elderly subjects, aged 65 and older, with that of younger subjects. Although the elderly constitute only 12% of the population, they are diagnosed with more than 50% of the cancers. The study consisted of 7,783 Japanese-American men, born from 1900-1919 and examined from 1965-1968. During 154,000 person-years of follow-up, 1,478 incident cases of cancer were identified. The incidence rate of cancer was high among the elderly (142.7 per 10,000 person-years) compared with younger subjects (48.2 per 10,000 person-years), yielding a significant (p < 0.05) rate ratio of 3.0. Of the site-specific cancers, prostate cancer showed the highest rate ratio of 7.0, followed by oral, stomach, lung, and colon cancer. In addition, the five-year age-specific rates for stomach and colon cancer rose directly with age. A similar pattern was also observed for lung and prostate cancer in men before age 80, but the rates declined thereafter. The findings from this study suggest that the reduction in risk for cancers of the prostate, oral cavity, stomach, lung, and colon must be viewed as a major goal for improving the public health in the elderly population.
 ...
PMID:Cancer in the elderly: a prospective study among Hawaiian Japanese men. 134 46

Several somatostatin analogs with recently synthesized acetylated N terminus were assayed in vivo for their effects on sodium pentobarbital-stimulated growth hormone (GH) levels in fed male rats and gastrin-releasing peptide (14-27)-stimulated gastrin levels in fasted male rats. The binding characteristics of these analogs to somatostatin receptors were also examined in various human tumors and normal tissues. The analog RC-101-I, injected at a dose of 0.1 micrograms/100 g body wt, significantly suppressed GH release (P less than 0.01) for at least 2 hr. Analog RC-160-II caused the longest inhibition of GH release, greater than that induced by nonacetylated parent analog RC-160, with GH levels showing significant suppression (P less than 0.01) for more than 3 hr. Analogs RC-160-II and RC-101-I and RC-160, injected at a dose of 1.0 micrograms/100 g body wt, significantly (P less than 0.01) suppressed gastrin-releasing peptide (14-27)-stimulated serum gastrin. Analog RC-101-I was active in this test at a dose of 0.1 micrograms/100 g body wt. RC-160-II showed significant binding to somatostatin-14 receptors in all investigated tissues (human colon, human colon cancer, breast cancer, human pancreas and pancreatic cancer, human prostate and prostate cancer, and rat cerebral cortex), but there were marked variations in binding affinities among various normal and cancerous tissues. The highest affinity was found in membranes of colon cancer (Ka = 18.4 nM-1) and breast cancer (Ka = 12.46 nM-1). The binding affinity of RC-160-II to somatostatin receptors in membranes of the breast cancer was similar to that of RC-160. RC-101-I showed higher binding affinity to somatostatin-14 receptors than RC-160 in human breast, pancreatic, and prostate cancer. With the exception of breast cancer tissue, the binding affinity of RC-101-I was significantly lower than that of RC-160-II in membranes of all investigated tissues. It can be concluded that acetylated somatostatin analogs RC-101-I and RC-160-II possess prolonged and enhanced biological activities in suppressing serum GH and gastrin in rats. Significant variations in binding affinities for these analogs in different tissues and various tumors suggest that differences may exist between somatostatin receptors in normal versus malignant tissues. This raises the possibility that some of these analogs could be used more selectively in the treatment of various neoplasms.
 ...
PMID:Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs. 134 89

Studies of activity and all-cancer mortality have inconsistent findings and are difficult to interpret, largely because cancer refers not to one disease but to many distinct, site-specific diseases. However, mounting evidence suggests that physical activity may be associated with decreased mortality from and incidence of certain types of cancers. In 15 of 18 studies, higher levels of occupational and/or recreational activity were inversely related to colon cancer incidence and mortality. One major study found activity to be negatively related to occurrence of breast cancer, and conflicting findings exist regarding the association between activity and prostatic cancer. Given the consistency in the direction and magnitude of the findings regarding activity and colon cancer, the presence of appropriate temporal relationships between measured exposure and outcome, the suggestion of dose-response relationships and the existence of plausible biological mechanisms, including increased transit time and gut motility, the evidence supports the conclusion that activity is protective against colon cancer. Although that protective effect may be small, the attributable risk of colon cancer associated with inactivity may be quite high given the prevalence of inactivity in Western societies.
 ...
PMID:Cancer and the protective effect of physical activity: the epidemiological evidence. 143 71

Recent progress in elucidating the complex and heterogeneous interactions between malignancy and coagulation or fibrinolysis reactions in humans has clarified the pathogenesis of disseminated intravascular coagulation that occurs with malignancy and has revealed evidence for two distinct pathways of growth regulation based on production by tumor cells of initiators of thrombin formation versus plasminogen activators. We have proposed a preliminary classification of tumors (see Table 2) based on these interactions. Type I tumors are those in which the tumor cells are associated with an intact coagulation pathway that leads to thrombin formation at the tumor periphery but in which the tumor cells lack u-PA. Examples of tumors in this category include SCCL, malignant melanoma, and renal cell carcinoma. Type II tumors are those in which the tumor cells express u-PA but lack an associated coagulation pathway leading to thrombin formation. Examples of type II tumors include prostate cancer, colon cancer, breast cancer, and N-SCLC. Type III tumors are those that express neither of these pathways, or exhibit some other pattern of interaction. Obviously, this formulation must be regarded as hypothetical. However, this concept fits with the limited data available to date from clinical trials. More importantly, this hypothesis can be tested further by means of intervention aimed at interrupting pathways relevant to specific tumor types. Characterization of additional tumor types by the methods described should permit amplification of this classification of tumors and other patterns of interaction may be defined. Exploration of the coagulation-cancer interaction holds considerable promise for gaining new understanding of both the coagulation mechanism and tumor biology. Most intriguing is the prospect that imaginative approaches to cancer treatment may be devised that are not only relatively nontoxic and low cost, but also effective.
 ...
PMID:Pathways of coagulation/fibrinolysis activation in malignancy. 157 11

We installed a Kock continent reservoir in 103 patients after radical cystectomy or pelvic exenteration between Feb. 1986 and Dec. 1989. They consisted of 81 male and 22 female patients. Patients' age ranged from 30 to 78 years with the average being 63 years. Their original diseases were bladder cancer (96 patients), prostatic cancer (2), sigmoid colon cancer (2) and others (3), The Kock reservoir was made by the procedure described by D. G. Skinner et al. The mean operation time for reservoir creation was 220 minutes. In 99 patients with a Kock reservoir for more than 3 months, the capacity of the reservoir was 200-900 ml with the average being 490 ml and the frequency of self-catheterization was 4 to 6 times a day. Early complications occurred within 3 months in 27 (26%) patients. Complications directly related to the reservoir were urine leakage (5 patients), intestine reservoir fistula formation (3) and necrosis of the reservoir (1). Late complications occurred after 3 months in 25 (25%) patients. They consisted of difficulty of catheterization (9 patients), ureteral reflux from reservoir (2), hydronephrosis (8), abscess (4), metabolic acidosis (2) and others. The results indicated that this procedure is an appropriate urinary diversion since the quality of life in the patients with a Kock reservoir is better. However, after this procedure surgical complications were not infrequent. Therefore, this procedure should be performed in selected patients.
 ...
PMID:[Complications of Kock continent reservoir. Report of 103 cases]. 159 27


1 2 3 4 5 6 7 8 9 10 Next >>